Proqr Therapeutics N V Revenue Growth Rates (PRQR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Proqr Therapeutics N v   (NASDAQ: PRQR)
 

PRQR's Revenue Growth by Quarter and Year

Proqr Therapeutics N V 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRQR Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 17.81
3rd Quarter September 3.37
2nd Quarter June 4.33
1st Quarter March 4.76
FY 30.27

PRQRs Annual Revenue
Proqr Therapeutics N V 's Revenue in the fiscal year 2025 $ 17.81 millions
Proqr Therapeutics N V 's Revenue in the fiscal year 2024 $ 21.17 millions
Proqr Therapeutics N V 's Revenue in the fiscal year 2023 $ 0.00 millions
Proqr Therapeutics N V 's Revenue in the fiscal year 2022 $ 3.78 millions
Proqr Therapeutics N V 's Revenue in the fiscal year 2021 $ 1.60 millions




PRQR Revenue fourth quarter 2025 Y/Y Growth Comment
Proqr Therapeutics N V reported decline in Revenue in the fourth quarter 2025 by -15.85% to $ 17.81 millions, from the same quarter in 2024.
Despite modest results in the fourth quarter 2025, contraction in Proqr Therapeutics N V 's Revenue appears to be smaller than Company's recent average decline.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue growth. While Proqr Therapeutics N V ' s Revenue fall of -15.85% ranks overall at the positon no. 2759 in the fourth quarter 2025.


PRQR Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December -15.85 % - - -
3rd Quarter September -20.14 % 183.22 % 81.71 % -20.39 %
2nd Quarter June -36.23 % 418.32 % 32.32 % 241.38 %
1st Quarter March -1.45 % 590 % -44.88 % -
FY   -18.2 % 957.43 % 13.64 % -

Financial Statements
Proqr Therapeutics N V 's fourth quarter 2025 Revenue $ 17.81 millions PRQR's Income Statement
Proqr Therapeutics N V 's fourth quarter 2024 Revenue $ 21.17 millions Quarterly PRQR's Income Statement


PRQR Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December 428.63 % 401.66 % - -
3rd Quarter September -22.17 % -37.85 % 13.74 % -17.17 %
2nd Quarter June -9.03 % 40.58 % 87.14 % -22.05 %
1st Quarter March -77.52 % - - 370.37 %
FY (Year on Year)   -18.2 % 957.43 % 13.64 % -


Back to PRQR Growth rate Comparisons >> Back to PRQR Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #364
Overall #2759

Revenue Y/Y Growth Statistics
High Average Low
-15.86 % -15.86 % -15.86 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #364
Overall #2759
Revenue Y/Y Growth Statistics
High Average Low
-15.86 % -15.86 % -15.86 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Proqr Therapeutics N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
428.98 % 70.43 % -100 %
(Dec 31 2025)  


PRQR's IV. Quarter Q/Q Revenue Comment
Proqr Therapeutics N v achieved in the IV. Quarter 2025 above company average sequential Revenue doubling of 428.63%, to $ 17.81 millions, from $3.37 millions in the third quarter.
PRQR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Proqr Therapeutics N V 's Revenue growth quarter on quarter, overall rank is 67.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #25
Overall #67
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #25
Overall #67
Revenue Q/Q Growth Statistics
High Average Low
428.98 % 70.43 % -100 %
(Dec 31 2025)  


PRQR's IV. Quarter Q/Q Revenue Comment
Proqr Therapeutics N v achieved in the IV. Quarter 2025 above company average sequential Revenue doubling of 428.63%, to $ 17.81 millions, from $3.37 millions in the third quarter.
PRQR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Proqr Therapeutics N V 's Revenue growth quarter on quarter, overall rank is 67.


Proqr Therapeutics N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 17.81 $ 21.17 $ 0.00 $ 3.78 $ 1.60
Y / Y Revenue Growth (TTM) -15.86 % - - 135.83 % -
Year on Year Revenue Growth Overall Ranking # 3444 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -15.86 % - - 135.83 % -
Seq. Revenue Growth (TTM) Overall Ranking # 3616 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Proqr Therapeutics N V showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Dec 31 2025, Proqr Therapeutics N V 's annual Revenue surge would be -15.86% year on year to $18 millions.

In the Healthcare sector 439 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3444.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 160
Healthcare Sector # 440
Overall # 3444

Revenue TTM Y/Y Growth Statistics
High Average Low
-15.86 %
 -15.86 %
-15.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 160
Sector # 470
S&P 500 # 3616
Cumulative Revenue growth Comment
Proqr Therapeutics N V showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Dec 31 2025, Proqr Therapeutics N V 's annual Revenue fall would be -15.86% year on year to $18 millions.

In the Healthcare sector 439 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3444.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 160
Healthcare Sector # 440
Overall # 3444

Revenue TTM Y/Y Growth Statistics
High Average Low
-15.86 %
-15.86 %
-15.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 160
Sector # 470
S&P 500 # 3616




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRQR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Ardent Health Inc -0.08%$ -0.075 millions
Chemed Corporation-0.10%$ -0.103 millions
Embecta Corp -0.15%$ -0.153 millions
Bruker Corporation-0.24%$ -0.245 millions
Vaso Corporation-0.38%$ -0.376 millions
Bio techne Corp-0.54%$ -0.542 millions
Lftd Partners Inc -0.76%$ -0.763 millions
Xtant Medical Holdings Inc -0.82%$ -0.821 millions
Charles River Laboratories International inc -0.83%$ -0.830 millions
Koninklijke Philips Nv-1.04%$ -1.038 millions
Evotec Se-1.08%$ -1.078 millions
Pfizer Inc-1.16%$ -1.160 millions
Adapthealth Corp -1.21%$ -1.209 millions
Avantor Inc -1.36%$ -1.364 millions
Alpha Teknova Inc -1.42%$ -1.422 millions
Skinhealth Systems Inc -1.57%$ -1.569 millions
Pediatrix Medical Group Inc -1.71%$ -1.711 millions
Integra Lifesciences Holdings Corp-1.74%$ -1.744 millions
Edap Tms Sa-1.78%$ -1.783 millions
Vivos Therapeutics Inc -2.18%$ -2.178 millions
Absci Corp-2.26%$ -2.256 millions
Prestige Consumer Healthcare Inc -2.30%$ -2.303 millions
Perrigo Company Plc-2.52%$ -2.521 millions
Bionano Genomics Inc -2.60%$ -2.597 millions
Haemonetics Corporation-2.64%$ -2.636 millions
Amphastar Pharmaceuticals Inc -2.79%$ -2.790 millions
Strata Skin Sciences Inc-2.97%$ -2.966 millions
Plus Therapeutics Inc -3.19%$ -3.187 millions
Harvard Bioscience Inc -3.23%$ -3.226 millions
Brookdale Senior Living Inc -3.44%$ -3.439 millions


About Proqr Therapeutics N V Revenue Growth Rates (PRQR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Proqr Therapeutics N v (CIK 1612940).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-026713
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Proqr Therapeutics N v ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.